Talk:Programmed death-ligand 1: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| (4 intermediate revisions by the same user not shown) | |||
| Line 7: | Line 7: | ||
*2018 paper: ~ 70% durable response among those that discontinue d/t side effects[https://www.ncbi.nlm.nih.gov/pubmed/29437040] | *2018 paper: ~ 70% durable response among those that discontinue d/t side effects[https://www.ncbi.nlm.nih.gov/pubmed/29437040] | ||
*2018 paper: response rates are low in UCC and RCC, current PD-L1 tests not useful in UCC and RCC[https://www.ncbi.nlm.nih.gov/pubmed/29368638] | *2018 paper: response rates are low in UCC and RCC, current PD-L1 tests not useful in UCC and RCC[https://www.ncbi.nlm.nih.gov/pubmed/29368638] | ||
*2018 meta-analysis: PD-L1 is a poor prognosticator in RCC (HR~2.76)[https://www.ncbi.nlm.nih.gov/pubmed/29362922] | |||
==CPS and TPS== | |||
CPS in lymph nodes: | |||
*H&N: https://pubmed.ncbi.nlm.nih.gov/35420378/ https://pmc.ncbi.nlm.nih.gov/articles/PMC7413953/ | |||
*H&N cytology: https://pmc.ncbi.nlm.nih.gov/articles/PMC8810615/ | |||
*Breast: https://pmc.ncbi.nlm.nih.gov/articles/PMC10078903/ https://surgexppathol.biomedcentral.com/articles/10.1186/s42047-019-0033-z | |||
==References== | |||
{{Reflist|1}} | |||